source
- Experts review five decades of regulatory evolution at RAPS Convergence 2026At the opening plenary of RAPS Convergence 2026 in Charlotte, NC, specialists in medical device and pharmaceutical regulatory affairs gathered to discuss the field’s trajectory. They reflected on…
- AstraZeneca’s Etcamah fails Phase 3 trial, dashing hopes for $2.9 billion breast cancer marketAstraZeneca’s oral selective estrogen receptor degrader Etcamah was evaluated in the Phase 3 SERENA-4 trial as a first-line option for patients with ER-positive, HER2-negative advanced breast cance…